Swallowed sponge test to find Barrett's esophagus without an endoscopy
Tests a swallowed sponge device for spotting Barrett's esophagus in adults at risk.
Key facts
- Who runs it
- Cyted Health Inc
- Where
- Cordova, United StatesSee the site
- Trial code
- Registry title
- Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
- Status
- Recruiting
- People taking part
- 700 people, planned
- Started
- 5 Feb 2025
- Expected to end
- Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Barrett's Esophagus Test (LDT)
- Record updated
- 29 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with confirmed Barrett's esophagus who are having a standard endoscopy (a camera test of the food pipe). Before it, they swallow a capsule with a sponge that collects cells. The high-risk screening group closed in November 2025.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Confirmed Barrett's esophagus at least 1 cm (0.4 in) long. This can be without dysplasia (abnormal cells), with low-grade or high-grade dysplasia, or adenocarcinoma (a type of cancer).
- Earlier treatment
- People who already had endoscopic eradication therapy (EET, treatment to remove Barrett's tissue during endoscopy) cannot join. People who had stomach or esophagus surgery, including Nissen fundoplication, cannot join.
Main reasons for not taking part
- A previous endoscopy result that was unclear for dysplasia (indefinite for dysplasia)
- Trouble swallowing a pill the size of the capsule (8.5 mm across)
- Known or suspected enlarged veins in the stomach or esophagus (varices) or portal hypertension
- Blood-thinning medicines that cannot be stopped, or GLP-1 agonists that cannot be stopped for 1 week before the sponge test
- Heart attack or stroke in the past 6 months, a past tumor of the throat, or known or suspected pregnancy
The registry criteria, word for word
Show all 16 criteriaShow less
Who cannot take part
- Previous EGD result was indefinite for dysplasia
- Previous endoscopic eradication therapy (EET)
- Taking anti-thrombotic medications that cannot be discontinued
- Taking GLP-1 agonists that cannot be discontinued for 1 week prior to sponge administration
- Previous gastric or esophageal surgery (including Nissen fundoplication)
- Known or suspected portal hypertension
- History of oropharyngeal tumor
- History of myocardial infarction or cerebrovascular accident in past 6 months
- Current dysphagia (unable to swallow a pill the size of the capsule (8.5 mm dia.))
- Known or suspected gastric or esophageal varices
- Known or suspected to be pregnant (self-report for woman of child-bearing potential)
Other criteria
- High Risk Screening: Closed November 2025 Barrett's Esophagus Inclusion Criteria
- Undergoing a standard of care EGD (with or without endoscopic eradication therapy {EET})
- Willing to undergo non-endoscopic sampling with the study device prior to EGD (up to 6 weeks prior to EGD/EET or day of EGD/EET)
- Willing and able to sign informed consent
- Confirmed Barrett's Esophagus of length at least 1 cm or greater. This includes non-dysplastic Barrett's, low-grade dysplasia, high-grade dysplasia or adenocarcinoma
Where in United States
- Gastroenterology PracticeCordova, United StatesContact: Melissa Tuck, M.S.Taking people
About the trial
What the trial wants to find out
This study is looking at cells collected from the esophagus using a diagnostic device called the EndoSign® Cell Collection Device (a sponge on a thread). Subjects swallow a capsule, which dissolves in the stomach and releases a sponge that collects cells from the esophagus as the sponge is withdrawn using the thread. These cells will be tested to check for a condition called "Barrett's Esophagus."
Read full original descriptionShow less
The cells from the sponge will be tested using Cyted Health biomarkers and compared to the results from a regular endoscopy and any biopsies that are taken. To do this, we need sponge samples from people who might have Barrett's Esophagus based on their risk factors, and from people with Barrett's Esophagus.
Subjects will have one visit to have the Endosign Cell Collection Device administered prior to having a standard of care endoscopy. They will answer some questions about their medical history and experience with the cell collection procedure as part of the study. Data will be collected from medical records including post-endoscopy.
The 2 groups in the trial
- High Risk Screening without Barrett's Esophagus-closed 11/2025
Subjects with chronic GERD plus 3 other defined risk factors for Barrett's Esophagus (ACG) (e.g., age \>50, male, white, obese, family history) who have had a standard of care endoscopy in which no Barrett's esophagus was identified.
Treatment: Barrett's Esophagus Test (LDT)
- Barrett's Esophagus
Subjects with known Barrett's esophagus with or without dysplasia/cancer identified or confirmed (surveillance) via a standard of care endoscopy
Treatment: Barrett's Esophagus Test (LDT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Non-Endoscopic Detection of Barrett's Esophagus and Esophageal Neoplasia Using Methylation Biomarkers on Endosign® Cell Collection Device Samples
- Plain-language title
- Swallowed sponge test to find Barrett's esophagus without an endoscopyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 July 2026